Petrovic, Stanislava (55807329900)Stanislava (55807329900)PetrovicBogavac-Stanojevic, Natasa (6506171691)Natasa (6506171691)Bogavac-StanojevicLakic, Dragana (35170248800)Dragana (35170248800)LakicPeco-Antic, Amira (7004525216)Amira (7004525216)Peco-AnticVulicevic, Irena (55588791200)Irena (55588791200)VulicevicIvanisevic, Ivana (55588798700)Ivana (55588798700)IvanisevicKotur-Stevuljevic, Jelena (6506416348)Jelena (6506416348)Kotur-StevuljevicJelic-Ivanovic, Zorana (6603775254)Zorana (6603775254)Jelic-Ivanovic2025-06-122025-06-122015https://doi.org/10.11613/BM.2015.027https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930421453&doi=10.11613%2fBM.2015.027&partnerID=40&md5=ffc6a8226ac67f45e79ddea12b6f8686https://remedy.med.bg.ac.rs/handle/123456789/8377Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery. © 2015, Croatian Society of Medical Biochemistry and Laboratory Medicine.Acute kidney injuryBiomarkersCardiac surgeryChildrenCost effectiveness analysis